The FDA approved Cleveland Diagnostics' blood-based test to help diagnose high-grade prostate tumors and aid in biopsy decisions, the company announced. Dubbed IsoPSA, the in vitro diagnostic kit is ...
Quantum sensing technologies test existing privacy frameworks severely because they bypass the physical boundaries—walls, distance, the opacity of the human body—on which existing doctrine depends, ...
ServiceNow implementations evolve through frequent configuration changes, scoped application releases, and scheduled platform upgrades. These changes elevate regression risk across mission-critical ...
SimpleScreen™ achieved 85% sensitivity for CRC and 22% for advanced precancerous lesions at 90% specificity. Performance improvements are due to optimized assay reagents, automated workflows, and a ...
Your source for the latest in AI Native Development — news, insights, and real-world developer experiences. Your source for the latest in AI Native Development — news, insights, and real-world ...
Non-animal framework based on new approach methodologies (NAMs) for chemical hazard identification and risk assessment. The framework comprises three modules: (1) high-throughput screening to address ...
The FDA has granted Cleveland Diagnostics’ IsoPSA test premarket approval (PMA) to help detect prostate cancer in men aged 50 years or older with elevated PSA levels. IsoPSA is a blood assay that ...
CLEVELAND--(BUSINESS WIRE)--Cleveland Diagnostics, Inc., a pioneering, commercial-stage precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results